Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs

Journal of Pharmacological and Toxicological Methods

Volumn 54, Issue 3, 2006, Pages 261-272

  Chen, Xian ^a   Cordes, Jason S ^a   Bradley, Jenifer A ^a   Sun, Zhuoqian ^a   Zhou, Jun ^a  

^a Groton Laboratories   (United States)

Author keywords

Action potential (AP); Arrhythmia; Early afterdepolarization (EAD); Preclinical models; QT prolongation; Torsade de pointes (TdP)

Indexed keywords

CISAPRIDE; DOFETILIDE; FLUOXETINE; MOXIFLOXACIN; RISPERIDONE; SOTALOL;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; EPICARDIUM; EXPERIMENTAL MODEL; FEMALE; HEART DEPOLARIZATION; HEART LEFT VENTRICLE; HEART MUSCLE POTENTIAL; HEART PERFUSION; HEART PROARRHYTHMIA; HEART VENTRICLE; NONHUMAN; OUTCOME ASSESSMENT; QT INTERVAL; QT PROLONGATION; RABBIT; RECORDING; REPRODUCIBILITY; VALIDATION STUDY;

ACTION POTENTIALS; ANIMALS; CORONARY VESSELS; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; PERFUSION; PHARMACEUTICAL PREPARATIONS; RABBITS; TACHYCARDIA, VENTRICULAR;

ORYCTOLAGUS CUNICULUS;

EID: 33746283859     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.02.005     Document Type: Article

References (44)

1. Antimisiaris M., Sarma J.S., Schoenbaum M.P., Sharma P.P., Venkataraman K., and Singh B.N. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death. American Heart Journal 128 (1994) 884-891
2. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?. Journal of Electrocardiology 37 (2004) 15-24
3. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Current Opinion in Cardiology 17 (2002) 43-51
4. Antzelevitch C., Shimizu W., Yan G.X., and Sicouri S. Cellular basis for QT dispersion. Journal of Electrocardiology 30 (1998) 168-175
5. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences 24 (2003) 619-625
6. Chen X., Cass J.D., Bradley J.A., Dahm C.M., Sun Z., Kadyszewski E., et al. QT prolongation and proarrhythmia by moxifloxacin: Concordance of preclinical models in relation to clinical outcome. British Journal of Pharmacology 146 (2005) 792-799
7. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. Journal of Clinical Psychiatry 46 (1985) 32-37
8. Di Diego J.M., Belardinelli L., and Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108 (2003) 1027-1033
9. Dresser G.K., Spence J.D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 38 (2000) 41-57
10. Fermini B., and Fossa A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews: Drug Discovery 2 (2003) 439-447
11. Glassman A.H., and Bigger Jr. J.T. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry 158 (2001) 1774-1782
12. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology 41 (2003) 14-24
13. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology 14 (2003) 287-294
14. Isbister G.K., Bowe S.J., Dawson A., and Whyte I.M. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Journal of Toxicology. Clinical Toxicology 42 (2004) 277-285
15. James A.F., Choisy S.C., and Hancox J.C. Recent advances in understanding sex differences in cardiac repolarization. Progress in Biophysics and Molecular Biology (2005)
16. Joshi A., Dimino T., Vohra Y., Cui C., and Yan G.X. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: The role of experimental models. Journal of Electrocardiology 37 (2004) 7-14
17. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models: Predicting Torsades de Pointes. Journal of Pharmacological and Toxicological Methods 52 (2005) 46-59
18. Lherm T., Lottin F., Larbi D., Bray M., Legall C., and Caen D. Torsade de pointes after poisoning with fluoxetine alone. Presse Medicale 29 (2000) 306-307
19. Liu T., Choi B.R., Drici M.D., and Salama G. Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with Long QT 2. Journal of Cardiovascular Electrophysiology 16 (2005) 516-524
20. Liu L.P., Yang L., Zhao Z., and Chen Q. Gender-related differences of ventricular repolarization in LQT2 rabbit model. Sheng Li Xue Bao 57 (2005) 749-754
21. Malik M., and Camm A.J. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling. Drug Safety 24 (2001) 323-351
22. Mattioni T.A., Zheutlin T.A., Sarmiento J.J., Parker M., Lesch M., and Kehoe R.F. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Annals of Internal Medicine 111 (1989) 574-580
23. Milberg P., Ramtin S., Monnig G., Osada N., Wasmer K., Breithardt G., et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. Journal of Cardiovascular Pharmacology 44 (2004) 278-286
24. Moss A.J. The QT interval and torsade de pointes. Drug Safety 21 Suppl 1 (1999) 5-10 (discussion 81-17)
25. Peters N., Cabo C., and Wit A. Arrhythmogenic mechanisms: Automaticity, triggered activity and reentry. In: Zipes D., and Jalife J. (Eds). Cardiac electrophysiology: From cell to bedside (1999), W.B. Saunders Company, Philadelphia 345-356
26. Pham T.V., and Rosen M.R. Sex, hormones, and repolarization. Cardiovascular Research 53 (2002) 740-751
27. Poelzing S., and Rosenbaum D.S. Cellular mechanisms of Torsade de Pointes. Novartis Foundation Symposium 266 (2005) 204-217 (discussion 217-224)
28. Ravin D.S., and Levenson J.W. Fatal cardiac event following initiation of risperidone therapy. Annals of Pharmacotherapy 31 (1997) 867-870
29. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
30. Roden D.M. Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes. Pacing and Clinical Electrophysiology 21 (1998) 1029-1034
31. Ruan Y.F., Liu N., Zhou Q., Li Y., and Wang L. Experimental study on the mechanism of sex difference in the risk of torsade de pointes. Chinese Medical Journal 117 (2004) 538-541
32. Salata J.J., Jurkiewicz N.K., Jow B., Folander K., Guinosso Jr. P.J., Raynor B., et al. IK of rabbit ventricle is composed of two currents: Evidence for IKs. American Journal of Physiology 271 (1996) H2477-H2489
33. Spier S.A., and Frontera M.A. Unexpected deaths in depressed medical inpatients treated with fluoxetine. Journal of Clinical Psychiatry 52 (1991) 377-382
34. Tei Y., Morita T., Inoue S., and Miyata H. Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 45 (2004) 450-451
35. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453-2459
36. Valentin J.P., Hoffmann P., De Clerck F., Hammond T.G., and Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. Journal of Pharmacological and Toxicological Methods 49 (2004) 171-181
37. van de Loo A., Klingenheben T., and Hohnloser S.H. Amiodarone therapy after sotalol-induced torsade de pointes: Prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects. Zeitschrift fur Kardiologie 83 (1994) 887-890
38. Walker A.M., Szneke P., Weatherby L.B., Dicker L.W., Lanza L.L., Loughlin J.E., et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. American Journal of Medicine 107 (1999) 356-362
39. Wu Y., Carlsson L., Liu T., Kowey P.R., and Yan G.X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. Journal of Cardiovascular Electrophysiology 16 (2005) 898-904
40. Xu X., Yan G.X., Wu Y., Liu T., and Kowey P.R. Electrophysiologic effects of SB-237376: A new antiarrhythmic compound with dual potassium and calcium channel blocking action. Journal of Cardiovascular Pharmacology 41 (2003) 414-421
41. Yan G.X., and Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 93 (1996) 372-379
42. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
43. Yan G.X., Rials S.J., Wu Y., Liu T., Xu X., Marinchak R.A., et al. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. American Journal of Physiology: Hear and Circulatory Physiology 281 (2001) H1968-H1975
44. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 (2001) 2851-2856